Lupin Acquires Nanomi, Heading Toward Complex Injectables Space
Pharmaceutical major Lupin Limited recently announced the acquisition of Nanomi B.V. in the Netherlands. With this acquisition, Lupin has made its foray into the technology intensive complex injectables space.
Nanomi has patented technology platforms to develop complex injectable products. Nanomi has a rich talent pool of scientists who would be backed by Lupin’s global R&D and manufacturing teams.
Commenting on the acquisition, Ms. Vinita Gupta, Chief Executive Officer, Lupin Limited, said “We are very pleased with the acquisition of Nanomi. With the use of Nanomi’s proprietary technology platform, Lupin would be able to make significant in‐roads into the niche area of complex injectables.”
Lupin is an innovation-led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti‐Infective, and NSAID space and holds global leadership positions in the Anti‐TB and Cephalosporin segment. Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the third largest Indian pharmaceutical company by revenues. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS). For more information, visit www.lupinworld.com.
Total Page Views: 1702
